How Oncotarget is Boosting Cancer Research

Cancer is undoubtedly one of the most dangerous killer diseases in the world. Despite its cure remaining relatively unknown, cancer is a well-researched disease. Unfortunately, the greatest challenges that most researchers encounter is publishing their findings. More often than less, this is caused by the inadequacy of journals that can publish the findings. Oncotarget is a journal that is wholly dedicated to publishing findings of cancer research. The journal has become renowned for giving researchers a platform through which they can communicate their insights about cancer to the world.

Since being founded in 2010, Oncotarget’s stature has grown in leap and bounds. This prominent journal only focuses on cancer research and oncological studies. It is published weekly, and it seeks to reach out to cancer researchers whose works were previously unpublished. Articles published in Oncotarget are subjected to a stringent peer review process. This goes a long way in ensuring that they meet the highest scientific, ethical, and academic standards. Despite the fact that all articles published on Oncotarget are in English, articles are accepted from researchers in different parts of the world. Visit Oncotarget’s profile page at Facebook.

How Oncotarget Came into Being

The journal’s founders are Andrei V. Gudkov and Mikhail Blagoskonny. These are renowned experts in oncology besides being notable cancer researchers. The two serve on the journal’s editorial board besides being co-editors-in-chief. Their prominence within the research fraternity has enabled Oncotarget to gain immense popularity. The two have put in place an incredible peer review process. To achieve the highest scientific standards, they have brought on board competent researchers and healthcare professionals who oversee the review process.

Follow: https://twitter.com/oncotargetjrnl?lang=en

Oncotarget prides itself in being in the exclusive class of medical journals that are indexed on Medicus/MEDLINE/PubMed, BIOSIS, Scopus, and the Science Citation Index previews. Although its focus is cancer and oncology research, Oncotarget’s editorial board accepts articles that are related to the two disciplines. The journal is an imprint of Impact Journals. All its articles are freely available to the public since it is an open source journal. To achieve its objectives, Oncotarget has continued to partner with renowned academic and research institutions including Harvard, Columbia, and John Hopkins Universities, and the Roswell Cancer Institute.